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Introduction
Lithium (Li) is the 'gold standard' for the prophylaxis
of bipolar affective disorder (BPD), a disease which is
characterized by recurrent episodes of mania and
depression accompanied by changes in psychovegeta-
tive function, cognitive performance, and general
health.
Although Li preparations have been used for over
50 years, the cellular mechanisms of its action and
how it exerts its therapeutic effect remain not fully
understood. The pathophysiology of BPD is complex
and still unclear but Li seems to target at least several
abnormalities observed in mood disorders. Substitut-
ing for sodium, Li stabilizes numerous cellular
processes [1]. It has a direct influence on signal trans-
duction by modulating second messengers synthesis.
Li was also shown to modulate glutaminergic and
GABA-ergic neurotransmission [2,3]. 
Mood disorders are not only neurotransmission
defects but are linked with structural changes of the
nervous system and profound rearrangements in other
integrative systems of the body [4]. More and more
glial, neuroendocrine and immunologic dysfunctions
seem to be recognised as contributing to mood disor-
ders' pathogenesis [5-8].  In this context possible cyto-
protective capacity of lithium salts, although debated,
seems very promising for both neuron and glial regen-
eration and for possible preservation of the intact func-
tion of the immune cells [9-12]. 
Cytoprotective effects of Li are mainly attributed
to: (1) increasing amounts of cytoprotective proteins
such as Bcl-2 and decreasing proapoptotic proteins –
Bax and p53, (2) inhibition of glycogen synthetase
kinase-3 (GSK-3) and (3) protein kinase C (PKC) acti-
vation [9,13-16]. Thus, it is conceivable that affecting
the same mechanisms of survival or death Li+ may
exert a cytoprotective effect on other cell types. How-
ever, available data concerning the mechanisms of Li
effects on cells other than neurons including the
immune system cells are fragmentary and contradicto-
ry [7,9,17-24]. In this work we have tested the hypoth-
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esis of the general anti-apoptotic activity of Li salts  in
non-neuronal cells of lymphoid derivation.
Materials and methods
MOLT-4 cells were a courteous gift of Medical Chemistry Depart-
ment, Medical University of Gdañsk. Cell culture media, antibi-
otics (penicillin/streptomycin) and fetal bovine serum (FBS), lithi-
um carbonate (Li2CO3), campthotecin, Hoechst 33342, 5,5',6,6'-
tetrachloro-1,1',3,3' tetraethylbenzimidazolycarbocyanine iodide
(JC-1),  RNAse, propidium iodide (PI) and Tween were purchased
from Sigma-Aldrich (Germany). Annexin-V-FLUOS Staining Kit
was from Roche and all the cytometry consumables were from BD
Biosciences (Belgium).
Cell culture and drug treatment. Cells were cultured at 37 °C
in RPMI medium supplemented with 10% FBS, 100 U/ml peni-
cillin and 100 μg/ml streptomycin in a 95% air, 5% CO2 humid-
ified incubator. Cells were seeded at 0.5 × 106 cells per ml in 24
well plates and  grown without or with Li carbonate added to the
final concentration of 0.5 μM; 1 μM; 1.5 μM  (as equivalent of
the therapeutic Li concentrations) and 2 μM;10 and 20 μM, in the
presence or absence of 1 μg/ml of campthotecin for 4, 24, 48 and
72 hours. At times specified cells were harvested, washed with
PBS and immediately further processed. Early apoptosis was
identified as significant mitochondrial depolarization of cells
stained with fluorescent mitochondrial potential cyanine probe
JC-1 [25-27], while later stages of apoptosis by estimation of
annexin V binding and by detection of cells containing sub-G1
amounts of DNA by staining with propidium iodide (PI) [28-30].
Apoptotic cell morphology was visualised with a DNA binding
dye – Hoechst 33342 [31].
Mitochondrial potential changes. In order to detect the mito-
chondrial depolarization as an early feature of the incipient apop-
tosis, cells were incubated with 10 µg/mL 5,5',6,6'-tetrachloro-
1,1',3,3'-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) for
15 minutes at room temperature and their green and red fluores-
cence corresponding to JC-1 monomers and aggregates respective-
ly was assessed by FACS. Cells exhibiting an increase of green
fluorescence as compared to the control were considered to have
their mitochondria depolarized.
Annexin V binding. Later stage of apoptotic process, the mem-
brane symmetrization leading to the externalization of the phos-
phatidylserine was assessed by Annexin V binding, while late
apoptotic and necrotic cells were excluded by simultaneous PI
staining using the Annexin-V-FLUOS Staining Kit (Roche). Cells
were suspended in the binding buffer and incubated with FITC-
conjugated annexin V and PI for 15 minutes at room temperature,
then immediately analyzed by FACS. 
Cell cycle and apoptosis analysis by DNA content. Latest stages
of apoptosis leading to depletion of apoptotic cells of their DNA,
as well as the proportion of cells in various phases of the cell cycle
(G1, S, G2/M) were assessed after staining cellular DNA with the
PI. Cells were fixed with ice cold ethanol, washed and incubated
with the staining mixture containing Tween-20, RNAse and PI for
15 minutes at 37°C, then analyzed by FACS. All cytometric analy-
ses were performed using the FACScan flow cytometer (BD Bio-
sciences). Raw data were acquired with dedicated CellQuest soft-
ware (BD Biosciences) and analyzed with WinMDI 2.9 (J. Trot-
ter;The Scripps Institute).
Hoechst 33342 staining. Harvested cells were stained with 5
μg/ml  Hoechst 33342 in PBS. Stained cells were transferred
onto microscopic slides and analyzed under the fluorescence
microscope Eclipse TS100 (Nikon) with the 400-420 nm bypass
filter. Photographs were collected using NIS Elements Nikon
software.
Statistical analysis. All statistical analyses were performed with
Statistica 7.1 software under the Medical University of Gdañsk
license agreement. P-values of ≤0.05 were taken to be significant
in all tests. 
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Fig.  1. Therapeutic concentrations of
lithium exert cytoprotective effect
against camptothecin-induced apoptosis
of MOLT-4 lymphoid cells. The experi-
ment was performed as in Materials and
Methods. Cells were incubated untreat-
ed (A,B) or  treated with camptothecin
(C,D) for 4 hours without or with indi-
cated concentrations of Li+ and the pro-
portion of early apoptotic cells was
assessed by detection of mitochondrial
membrane depolarization with JC-1
(A,C) and by membrane symmetrization
with Annexin V binding (B,D). Signifi-
cant increase of early apoptotic cells
(p<0.05) could be seen in the samples
treated with above 1.5 mM Li+ only
(A,B), while lithium concentrations
between 0.5 and 2 mM were significant-
ly reducing the proportion of apoptotic
cells in camptothecin-treated samples
(B,D); p<0.01 for all Li+ concentrations
marked as 'cytoprotective'. Box-and-
whisker plots show mean, ±SD, and
±SEM, N=6.
Results
There were significant differences in the effect of Li
salt on the various stages of the apoptotic process,
depending on its being spontaneous or camptothecin-
induced.
First, we have observed a mildly proapoptotic
effect of Li on the proportion of spontaneously apop-
totic MOLT- 4 cells assessed by the mitochondrial
depolarization, where the proportion of depolarized
cells started to rise at 1 mM Li+ and then rose propor-
tionally to the concentration of lithium salt, reaching
significant difference from the untreated control (Fig.
1 A). This effect was generally paralleled by the
appearance of apoptotic, Annexin V – binding cells
upon treatment with 10 mM Li+ (Fig. 1 B).
Interestingly, the effect exerted by Li+ over MOLT-
4 cells induced to undergo apoptosis by treatment with
the topoisomerase II inhibitor, camptothecin, was
clearly biphasic. Namely, low (therapeutic) concentra-
tions of Li+ had a significant effect stabilizing the
mitochondrial membrane potential (Fig. 1 C) and
decreasing the external surface binding of Annexin V
(Fig. 1 D), while 10 mM Li+ increased the proportion
of early apoptotic cells enumerated both ways  above
the control (untreated) level (Fig. 1 C, D). 
Also the effect of Li+ on late apoptosis (cellular
DNA fragmentation and removal) depends on its con-
centration and on the manner of apoptosis induction.
Thus, in the untreated cells, only the supraclinical (10
and 20 mM) concentrations of Li+ induced significant
apoptosis as judged by the appearance of cells con-
taining sub-G1 amounts of DNA (Fig. 2 A-C,  Fig. 3
A).
Increased proportion of sub-G1 cells appearing due
to Li+ treatment was  accompanied by reduced propor-
tion of S phase cells, but this effect showed only after
24 hour treatment (Fig. 3 B) and disappeared after 48
hours of incubation with Li+, at which time the pro-
portion of sub-G1 cells in 10 and 20 mM Li+-treated
samples did not differ from that seen after 24 hours
(Fig. 3 C, D). 
Interestingly enough, while the effect on Li+ in
untreated cells was rather pro-apoptotic, that exerted
over the MOLT-4 cells in which apoptosis was induced
by camptothecin (blockade of topoisomerase), was
clearly anti-apoptotic and cytoprotective. This effect
could be demonstrated for all three phases of induced
apoptosis. Thus, Li+ at 0.5-2 mM significantly
decreased the proportion of cells that exhibited mito-
chondrial depolarization (Fig. 1 C) and the proportion
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Fig.  2. Supratherapeutical concentrations of
Li+ protect the camptothecin-treated cells
from apoptotic DNA loss. MOLT-4 cells
were incubated without (A,D), with 1 mM
Li+ (B,E) or with 20 mM Li+ (C,F) for 24
hours, without (A-C) or with simultaneous
presence of camptothecin as in Materials and
Methods (D-F). DNA contents was estimated
by flow cytometry using the propidium
iodide (PI) staining . 1 mM lithium had no
apparent effect on the proportion of sub-G1
cells either untreated (B) or camptothecin –
treated (E). Lithium at 20 mM reduced the
proportion of camptothecin-free cells in S-
phase (C), and markedly reduced the propor-
tion of subG1 cells among those treated with
camptothecin, with simultaneous increase of S
and G2/M cells' proportion (F). Cytometric
histograms illustrate one experiment represen-
tative for three giving the same results (com-
pare Fig. 3 and 4).
of Annexin V – biding cells (Fig. 1 D). On the other
hand, appreciable and significant effect of Li+ prevent-
ing the formation of sub-G1 cells could be seen only at
10 and 20 mM of lithium salt, after both 24 and 48
hour treatment (Fig. 2 D-F, Fig. 4 A, C). Some con-
centration dependency of the anti-apoptotic effect of
Li+ on camptothecin-treated cells could also be
seen;thus, 2 mM Li+ had no protective effect, while
that of 20 mM Li+ was significantly higher than that
exerted by 10 mM Li+ (Fig. 4). Accordingly, morpho-
logical changes in the nuclei of MOLT-4 cells treated
with either Li+ or camptothecin only, or with their
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Fig.  3. Supratherapeutical concentra-
tions of Li+ are inducing increase in
spontaneous apoptosis of MOLT-4 cells.
Proportions of sub-G1 and S-phase cells
were assessed by flow cytometry after 24
(A,B) or 48 hours of treatment with indi-
cated concentrations of Li+ (C,D) as in
Materials and Methods. 10 and 20 mM
Li+ resulted in significant increase of the
proportion of subG1 cells after 24 hours,
as compared to untreated control,  and
for 20 mM Li+ also after 48 hours (N=3,
*p<0.001). The effect was reciprocated
by loss of S-phase cells seen in 24-hour
assay (B) but not after 48 hours (D).
Fig.  4. Supratherapeutical concentra-
tions of Li+ protect the camptothecin-
treated cells  from apoptotic DNA loss.
Proportions of subG1 and S-phase cells
were assessed by flow cytometry after
24 (A,B) or 48 hours of treatment with
indicated concentrations of Li+ (C,D)
as in Materials and Methods. 10 and 20
mM Li+ resulted in significant decrease
of the proportion of subG1 cells after
24  and 48 hours of simultaneous treat-
ment with Li and camptothecin (A,C),
as compared to untreated control (not
shown) and to 2 mM Li+-treated cells
(N=3, *p<0.01, ***p<0.0001). The
effect was reciprocated by significant
increase of S-phase cells seen in 24-
and 48-hour assay (B,D;N=3, *p<0.01,
**p<0.001, ***p<0.0001).
combination, could be seen. Thus, treatment with Li+
only did not change the proportion of apoptotic cells
displaying fragmented, focally condensed chromatin
(Fig. 5 A, B), while treatment with camptothecin only
resulted in the vast majority of the cells to become
morphologically apoptotic, as judged by Hoechst
33342 staining (Fig. 5 C). Finally, 20 mM Li+ added
simultaneously with camptothecin completely abol-
ished its proapoptotic level (Fig. 5 D).
Similarly to the effects of Li+ on the proportions of
otherwise untreated sub-G1 and S phase cells, also the
Li+-dependent reduction of sub-G1 fraction of MOLT-
4 cells treated with camptothecin was reciprocated by
a significant  increase in the proportion of cells in S-
phase of the cycle (Fig. 2 F, Fig. 4 B). Unlike in the
case of untreated cells, the effect was preserved also in
the cells that were treated with Li+ and camptothecin
over 48 hours (Fig. 4 D).
Discussion
We have demonstrated here a variable, dose dependent
effect of treatment with therapeutic and supratherapeu-
tic doses of lithium salts on the survival and sponta-
neous and camptothecin-induced apoptosis of MOLT-
4 cells. Thus, in otherwise untreated cells, Li+ acted
mostly pro-apoptotically, and that mainly at suprather-
apeutic concentrations above 2 mM, while in the case
of camptothecin-induced apoptosis, therapeutic Li+
concentrations  were anti-apoptotic and thus cytopro-
tective. These effects were seen by any means of apop-
tosis assessment, including initial mitochondrial depo-
larization (JC-1 monomer fluorescence), membrane
symmetrization (Annexin V binding) and DNA frag-
mentation/loss, suggesting that Li+ is either directly or
indirectly affecting all of them. 
The process of apoptosis is controlled by a diverse
range of cell signals, which may originate extracellu-
larly or intracellularly. There are two main apoptosis
pathways:(1) internal (mitochondrial) with caspase-9
playing the main role and (2) Fas or TNF receptor
induced with central role of caspase-8. A number of
proapoptotic and cytoprotective proteins take part in
apoptosis regulation. In response to apoptosis-induc-
ing signals p53 regulates concentrations of some of
them. Level of Bax protein increases and of Bcl-2
decreases. Bcl-2/Bax ratio in the mitochondria deter-
mines the release of cytochrome c leading to apopto-
some formation. The apoptosome consists of
cytochrome c, Apaf-1 protein and procaspse-9 and its
formation activates caspase cascade leading the cell to
apoptosis [31-33]. Thus, the mechanisms of both pro-
and anti-apoptotic Li+ activity seen by us may be com-
plex. 
Concerning its modulation of the mitochondrial
potential, Li+ is known to substitute for Na+, and to
accumulate in the cell displacing intracellular Na and
in turn also intracellular Ca [1]. Thus, substitution of
sodium ions by Li stabilizes numerous intracellular
processes and may be responsible for its action on
mitochondria [2].
Chronic Li administration has been reported to
induce a robust elevation in the levels of the cytopro-
tective protein Bcl-2 when measured in the frontal cor-
tex, hippocampus, and striatum. Elevated Bcl-2 not
only protects the neurons from apoptosis but has also
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Fig.  5. Supratherapeutical Li+ prevents
DNA damage and chromatin fragmenta-
tion induced by camptothecin. Cells
were cultured without treatment (A)
with 2 mM Li+ (B) with 2 mM Li+ and
camptothecin (C) or with 20 mM Li+
and camptothecin for 72 hours,  stained
with Hoechst 33342 and their fluores-
cence recorded as in Materials and
Methods. Cells treated with camp-
tothecin and therapeutical Li+ (2 mM)
show general signs of apoptotic chro-
matin fragmentation (C) which is absent
from most cells treated with camp-
tothecin in te presence of 20 mM Li+
(D). Pictures show the representative
results of  one of three experiments.
been proven to result in better axonal regeneration in
mammals [34-37]. In rabbits, pretreatment with lithi-
um prevented aluminum-induced cytochrome c
translocation and thus initiation of apoptosis [38]. Li
can also induce decrease in Bax and p53 proteins and
inhibits procaspase-3 cleavage to caspase-3 [38].  The
latter is supported by the observation that Li prevents
apoptosis evoked by different substances including
colchicine exerting its action through caspase-3 activa-
tion [39-41], which in fact agrees with our observa-
tions. 
Li also influences glycogen metabolism which is
involved in cell proliferation, differentiation and apop-
tosis [42,43]. GSK-3 causes phosphorylation which
inhibits glycogen synthase, simultaneously glyco-
genolysis is activated. GSK-3 has numerous  cellular
targets, namely transcription factors, cytoskeleton pro-
teins and cell division involved molecules including
AP-1, cyclic AMP response element binding protein
(CREB), heat shock factor-1, nuclear factor of activat-
ed T cells NF-AT, c-Myc, beta-catenin, CCAAT/
enhancer binding protein, and NF?B. Generally, active
GSK-3 is proapoptotic and its inhibition is antiapop-
totic [44,45]. Li inhibits GSK-3 both directly (substi-
tuting for cofactory magnesium ions) and indirectly.
Other changes resulting from Li-induced GSK-3 inhi-
bition were shown in proliferating thyreocytes, name-
ly an increase in Jun bound to DNA, CREB activity
reduction and lower MAP1B and Tau phosphorylation
[46-49]. Wnt glycoproteins, belonging to the pathway
activated by the GSK-3 inhibition (e.g. resulting from
lithium treatment), are involved in embryogenesis,
stem cell development, cell proliferation and axonal
plasticity [50]. In the absence of Wnt,  GSK-3 phos-
phorylates beta-catenins leading to their degradation,
which is prevented by Li+. Beta-catenins,  accumulat-
ing in the cell nuclei when GSK-3 is inhibited, bind
with T-cell-specific transcription factor (TCF) and
activate a number of genes, possibly involved in the
cell survival [46,47].
Another proposed Li action is through protein
kinases which catalyse phosphorylation of the target
proteins and subsequently take part in the regulation of
the cell respose to the stimuli. Li treatment leads to
diacyloglycerol (DAG) accumulation and activation of
the protein kinase C (PKC) [46]. PKC targets two pro-
teins, both involved in neuroplasticity, GAP-43
(growth-associated protein) and MARCKS (myristoy-
lated alanine rich C kinase substrate). In cerebellar
granule cells Li has been shown to induce axonal
remodeling resembling the changes seen with GAP-43
overexpression [46,47,51].
A growing body of data suggests that bipolar dis-
ease BPD is not only a defect in neurotransmission
mechanisms but arises from abnormalities in synaptic
and neuronal plasticity cascades, leading to an aberrant
information processing in critical synapses and circuits
[3,4,12,19]. Recent morphometric studies have been
investigating potential structural brain changes in
BPD, and there is evidence from a variety of sources
demonstrating significant volume reductions in sever-
al regions of CNS, as well as regional decrease in the
glia and neurons numbers and sizes [6,52,53]. 
In this context reports of a possible cytoprotective
capacities of Li have been enthusiastically welcomed
immediately noting that it may be important not only
in mood disorders but in neurodegenerative diseases.
Modulating GSK-3 activity Li reduced amyloid and
tau protein phosphorylation in transgenic mice, results
very promising for the possible Li use for Alzheimer
disease [10,54,55]. 
Data regarding the neuroprotective action of Li
have been recently reviewed, showing that although
postulated by many has only been proven by few [9].
It may be in line with our observation that the cyto-
protective effect of Li salts is dose dependent – in our
model at therapeutic concentrations the spontaneous
apoptosis is prevented, while higher concentrations
prove toxic and increase apoptosis. Interestingly, sig-
nificant anti-apoptotic effect in capthotecin-induced
model is achieved with either the therapeutic (for early
stages of apoptosis, including the mitochondrial depo-
larization and membrane symmetrization) or
supratherapeutic concentrations of lithium salts (which
result in protection from DNA fragmentation and loss).
Thus experimental data must be interpreted with cau-
tion before conclusions are drawn about the effect in
humans in vivo.
Li administration was recently linked to reduced
tumor incidence compared to the general population
[56]. It was shown to reduce proliferation in tumors
expressing high activity of GSK-3. In prostate cancer
Li decreases the expression of multiple DNA replica-
tion-related genes, including cyclin A, cyclin E, cell
division cycle 6 (cdc6), and cdc25C, all regulated by
GSK-3 dependent E2 factor during the cell cycle
[56,57]. 
In the light of our observations showing that the
treatment with Li+ not only reduced the camptothecin-
induced apoptosis, but in fact increased the proportion
of cells in the S phase of the cycle, it is also important
to stress, that shown cytoprotective properties of Li,
while very welcomed in some cases, might not be
desirable during cytostatic treatment [58-62]. Our
research clearly indicates that topoisomerase inhibitor
treatment might be severely jeopardized by simultane-
ous administration of the Li salts. Thus, in our opinion,
safety of lithium treatment during chemotherapeutic
intervention should be considered and needs further
evaluation.
Concluding, both the recent papers cited above
and our observations presented herein suggest that
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the cytoprotective action of Li+ is not limited to the
neurons and may be considered a generalized phe-
nomenon.
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